These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25333782)

  • 21. Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.
    Clayton AM
    J Infect Dis; 2016 Dec; 214(suppl 5):S506-S509. PubMed ID: 27920182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation and application of chikungunya pseudovirus containing double reporter genes.
    Su C; Ding K; Xu J; Wu J; Liu J; Shen J; Zhou H; Liu H
    Sci Rep; 2022 Jun; 12(1):9844. PubMed ID: 35701460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.
    Kam YW; Lee WW; Simarmata D; Le Grand R; Tolou H; Merits A; Roques P; Ng LF
    PLoS One; 2014; 9(4):e95647. PubMed ID: 24755730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
    Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
    J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Neutralization Assay Using an eGFP Chikungunya Virus.
    Deng CL; Liu SQ; Zhou DG; Xu LL; Li XD; Zhang PT; Li PH; Ye HQ; Wei HP; Yuan ZM; Qin CF; Zhang B
    Viruses; 2016 Jun; 8(7):. PubMed ID: 27367716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A neutralization assay for chikungunya virus infections in a multiplex format.
    Weber C; König R; Niedrig M; Emmerich P; Schnierle BS
    J Virol Methods; 2014 Jun; 201():7-12. PubMed ID: 24552952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort.
    Yoon IK; Srikiatkhachorn A; Alera MT; Fernandez S; Cummings DAT; Salje H
    Int J Infect Dis; 2020 Jun; 95():167-173. PubMed ID: 32247051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune-Mediated Protection and Pathogenesis of Chikungunya Virus.
    Fox JM; Diamond MS
    J Immunol; 2016 Dec; 197(11):4210-4218. PubMed ID: 27864552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The neutralizing role of IgM during early Chikungunya virus infection.
    Chua CL; Sam IC; Chiam CW; Chan YF
    PLoS One; 2017; 12(2):e0171989. PubMed ID: 28182795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
    Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
    J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane.
    Jin J; Galaz-Montoya JG; Sherman MB; Sun SY; Goldsmith CS; O'Toole ET; Ackerman L; Carlson LA; Weaver SC; Chiu W; Simmons G
    Cell Host Microbe; 2018 Sep; 24(3):417-428.e5. PubMed ID: 30146390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection.
    Kumar R; Shrivastava T; Samal S; Ahmed S; Parray HA
    Appl Microbiol Biotechnol; 2020 Apr; 104(8):3209-3228. PubMed ID: 32076776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins.
    Quiroz JA; Malonis RJ; Thackray LB; Cohen CA; Pallesen J; Jangra RK; Brown RS; Hofmann D; Holtsberg FW; Shulenin S; Nyakatura EK; Durnell LA; Rayannavar V; Daily JP; Ward AB; Aman MJ; Dye JM; Chandran K; Diamond MS; Kielian M; Lai JR
    PLoS Pathog; 2019 Nov; 15(11):e1008061. PubMed ID: 31697791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus.
    López-Camacho C; Kim YC; Blight J; Lazaro Moreli M; Montoya-Diaz E; Huiskonen JT; Kümmerer BM; Reyes-Sandoval A
    Viruses; 2019 Apr; 11(4):. PubMed ID: 30987160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation of vesicular stomatitis virus pseudotype with Chikungunya virus envelope protein.
    Tong W; Yin XX; Lee BJ; Li YG
    Acta Virol; 2015 Jun; 59(2):189-93. PubMed ID: 26104337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines.
    Yoon IK; Alera MT; Lago CB; Tac-An IA; Villa D; Fernandez S; Thaisomboonsuk B; Klungthong C; Levy JW; Velasco JM; Roque VG; Salje H; Macareo LR; Hermann LL; Nisalak A; Srikiatkhachorn A
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003764. PubMed ID: 25951202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chikungunya Virus Fidelity Variants Exhibit Differential Attenuation and Population Diversity in Cell Culture and Adult Mice.
    Riemersma KK; Steiner C; Singapuri A; Coffey LL
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.
    Weger-Lucarelli J; Chu H; Aliota MT; Partidos CD; Osorio JE
    PLoS Negl Trop Dis; 2014 Jul; 8(7):e2970. PubMed ID: 25058320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-based analysis of Chikungunya virus E1 protein in membrane fusion.
    Kuo SC; Chen YJ; Wang YM; Tsui PY; Kuo MD; Wu TY; Lo SJ
    J Biomed Sci; 2012 Apr; 19(1):44. PubMed ID: 22520648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.
    Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL
    Front Immunol; 2020; 11():591885. PubMed ID: 33224148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.